Available Trials

Colorectal Cancer

A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)
  • Disease/Condition: Colon | Rectum
  • Principal Investigator: Jeremy Kortmansky
A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
  • Disease/Condition: Colon | Rectum
  • Principal Investigator: Jeremy Kortmansky
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Anant Deshpande
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Medication Adherence in Patients Treated with Capecitabine
  • Disease/Condition: Colon | Breast
  • Principal Investigator: Sarah Mougalian
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
  • Disease/Condition: Colon
  • Principal Investigator: Jeremy Kortmansky
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Hodgkin's Lymphoma | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Lymphoid Leukemia | Melanoma, skin | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
  • Principal Investigator: Scott Nicholas Gettinger
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
  • Disease/Condition: Bladder | Breast - Female | Breast - Male | Colon | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Urinary | Ovary | Rectum | Stomach | Phase I
  • Principal Investigator: Patricia LoRusso

Gastric and Esophageal

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
  • Disease/Condition: Other Digestive Organ
  • Principal Investigator: Jeremy Kortmansky
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
  • Disease/Condition: Other Digestive Organ | Stomach
  • Principal Investigator: Stacey M Stein
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Anant Deshpande
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
  • Disease/Condition: Other Digestive Organ | Stomach
  • Principal Investigator: Jill Lacy
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
  • Disease/Condition: Esophagus | Other Digestive Organ | Stomach
  • Principal Investigator: Stacey M Stein
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
  • Disease/Condition: Liver | Other Digestive Organ
  • Principal Investigator: Stacey M Stein
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
  • Disease/Condition: Other Digestive Organ
  • Principal Investigator: Jeremy Kortmansky

Liver Cancer

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
  • Disease/Condition: Liver
  • Principal Investigator: Stacey M Stein
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
  • Disease/Condition: Liver | Other Digestive Organ
  • Principal Investigator: Stacey M Stein
A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination with Conventional Transarterial Chemoembolization (cTACE) in Patients with Advanced Intra-Hepatic Cholangiocarcinoma (ICC)
  • Disease/Condition: Liver
  • Principal Investigator: Todd Schlachter
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Hodgkin's Lymphoma | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Lymphoid Leukemia | Melanoma, skin | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
  • Principal Investigator: Scott Nicholas Gettinger
An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors
  • Disease/Condition: Esophagus | Liver | Other Digestive Organ | Pancreas | Stomach
  • Principal Investigator: Stacey M Stein
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors
  • Disease/Condition: Anus | Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I | Unknown Sites
  • Principal Investigator: Joseph Paul Eder

Pancreatic Cancer

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Anant Deshpande
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
  • Disease/Condition: Pancreas
  • Principal Investigator: Jill Lacy
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
  • Disease/Condition: Pancreas
  • Principal Investigator: Jill Lacy
Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
  • Disease/Condition: Pancreas
  • Principal Investigator: Kimberly L. Johung
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
  • Disease/Condition: Pancreas
  • Principal Investigator: Jill Lacy
An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer
  • Disease/Condition: Pancreas
  • Principal Investigator: Stacey M Stein
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase II Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
  • Disease/Condition: Breast - Female | Breast - Male | Lung | Pancreas | Phase I
  • Principal Investigator: Joseph W Kim